122 related articles for article (PubMed ID: 36945423)
1. Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.
Hladish TJ; Pillai AN; Pearson CAB; Toh KB; Tamayo A; Stoltzfus A; Longini IM
medRxiv; 2023 Mar; ():. PubMed ID: 36945423
[TBL] [Abstract][Full Text] [Related]
2. Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.
Hladish TJ; Pillai AN; Pearson CAB; Toh KB; Tamayo AC; Stoltzfus A; Longini IM
PLoS Comput Biol; 2024 May; 20(5):e1012128. PubMed ID: 38820570
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
4. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.
Patel MD; Rosenstrom E; Ivy JS; Mayorga ME; Keskinocak P; Boyce RM; Hassmiller Lich K; Smith RL; Johnson KT; Delamater PL; Swann JL
JAMA Netw Open; 2021 Jun; 4(6):e2110782. PubMed ID: 34061203
[TBL] [Abstract][Full Text] [Related]
5. An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region.
Cattaneo A; Vitali A; Mazzoleni M; Previdi F
Comput Methods Programs Biomed; 2022 Sep; 224():107029. PubMed ID: 35908330
[TBL] [Abstract][Full Text] [Related]
6. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
[TBL] [Abstract][Full Text] [Related]
7. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
[TBL] [Abstract][Full Text] [Related]
8. Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region.
Liu Y; Sandmann FG; Barnard RC; Pearson CAB; ; Pastore R; Pebody R; Flasche S; Jit M
medRxiv; 2021 Jul; ():. PubMed ID: 34282421
[TBL] [Abstract][Full Text] [Related]
9. Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.
Domínguez-Ramírez L; Solis-Tejeda I; Ayon-Aguilar J; Mayoral-Ortiz A; Sosa-Jurado F; Pelayo R; Santos-López G; Cortes-Hernandez P
Front Public Health; 2022; 10():1010256. PubMed ID: 36176536
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment.
Ngonghala CN; Taboe HB; Safdar S; Gumel AB
Appl Math Model; 2023 Feb; 114():447-465. PubMed ID: 36281307
[TBL] [Abstract][Full Text] [Related]
13. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance.
Chinnadurai R; Wu HHL; Cox E; Moore J; Clough T; Lamerton E; Donne R; O'Riordan E; Poulikakos D
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455248
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
Yang W; Shaman J
medRxiv; 2021 Nov; ():. PubMed ID: 34845460
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
16. Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand.
Anupong S; Chantanasaro T; Wilasang C; Jitsuk NC; Sararat C; Sornbundit K; Pattanasiri B; Wannigama DL; Amarasiri M; Chadsuthi S; Modchang C
Infect Dis Model; 2023 Dec; 8(4):1177-1189. PubMed ID: 38074078
[TBL] [Abstract][Full Text] [Related]
17. Impact of vaccine prioritization strategies on mitigating COVID-19: an agent-based simulation study using an urban region in the United States.
Tatapudi H; Das R; Das TK
BMC Med Res Methodol; 2021 Dec; 21(1):272. PubMed ID: 34865617
[TBL] [Abstract][Full Text] [Related]
18. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of child vaccination (5-11 y) on overall COVID-19 related hospitalizations and mortality in a context of omicron variant predominance and different vaccination coverage paces in Brazil.
Müller GC; Ferreira LS; Mesias Campos FE; Borges ME; Berg de Almeida G; Poloni S; Simon LM; Bagattini ÂM; Quarti M; Felizola Diniz Filho JA; Kraenkel RA; Coutinho RM; Camey SA; Kuchenbecker RS; Toscano CM
Lancet Reg Health Am; 2023 Jan; 17():100396. PubMed ID: 36437904
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
